Bimatoprost (Lumigan) - Product information and Uses

Bimatoprost which is sold under the brand name Lumigan is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.
It has also been used and prescribed off-label to lengthen eyelashes. Lumigan is a 0.03% solution of bimatoprost.Studies have shown once-daily bimatoprost 0.03% ophthalmic solution to be more effective than timolol twice daily in reduction of intraocular pressure (IOP) and as effective as or more effective than the prostaglandin analogues latanoprost and travoprost in reducing IOP

Bimatoprost - Availability And Packaging

Bimatoprost is available as Lumigan Eye Drops which is packaged in 3ml bottles containing 0.03% solution of Bimatoprost and contains benzalkonium chloride as a preservative.

Side Effects of Bimatoprost

The Possible side effects of Bimatoprost (Lumigan) are:

  • May cause blurred vision.
  • May cause eyelid redness.
  • May permanently darken eyelashes.
  • May cause eye discomfort.
  • May eventually cause permanent darkening of the iris to brown.
  • May cause a temporary burning sensation during use.
  • May cause thickening of the eyelashes.
  • It may cause unexpected growth of hair if applied inappropriately, on the cheek, for example.
  • It may cause infection if the one-time applicators which come with the genuine product are reused.
  • Lashes may grow so long that they become ingrown and scratch the cornea.
  • May cause darkening of the eyelid or of the area beneath the eye.


Bimatoprost (Lumigan) - Dosage

The recommended dosage of Lumigan is one drop in the affected eye(s) once daily in the evening.
Contact lenses should therefore be removed before use, and replaced no less than 15 minutes later. Other eye drops or ointments should be given no less than 5 minutes before or after bimatoprost.

Additional Information

Additional Info: Prescribing Information

Considerable portions of the text here is from and is reproduced here under the Creative Commons Attribution-ShareAlike License